Although concomitant driver gene mutations in EGFR, KRAS, BRAF and ALK were initially reported to be mutually exclusive events in NSCLC patients20,47, we detected 14 cases (4%) harbouring concurrent alterations among the tested driver genes. This evidence concerns the gene ALK and non-small cell lung carcinoma.